earliest
dissemin
vaccin
anim
design
target
two
highli
lethal
rabbitspecif
eid
european
rabbit
popul
myxoma
viru
mv
rabbit
hemorrhag
diseas
viru
rhdv
vaccin
base
natur
attenu
mv
strain
strain
select
low
virul
nonleth
high
immunogen
mainten
horizont
transmiss
essenti
ident
highli
pathogen
wildtyp
strain
except
disrupt
four
gene
two
known
virul
factor
abl
protect
lethal
mv
challeng
follow
vaccin
use
direct
inocul
importantli
transmit
cohous
rabbit
assess
seroconvers
immun
confer
transmiss
protect
onward
transmiss
less
effici
approx
longer
protect
subsequ
engin
express
rhdv
capsid
protein
transmiss
bival
vaccin
rhd
myxomatosi
laboratori
condit
bival
vaccin
shown
exhibit
similar
characterist
direct
inocul
immunogen
protect
essenti
anim
transmiss
directli
inocul
cohous
rabbit
substanti
drop
onward
transmiss
shown
perform
remark
compar
fashion
limit
field
trial
perform
island
estim
popul
wild
european
rabbit
vaccin
show
maintain
avirul
high
immunogen
follow
direct
inocul
transmiss
rate
studi
mv
select
genet
basi
dissemin
vaccin
due
abil
spread
rabbit
popul
high
speci
specif
mv
rabbit
also
decreas
potenti
spread
offspeci
target
within
environ
howev
use
normal
virul
pathogen
host
speci
target
selfdissemin
vaccin
platform
necessarili
requir
use
attenu
mv
strain
requir
clear
impact
dissemin
capac
vaccin
recent
selfdissemin
vaccin
approach
use
cytomegaloviru
cmv
betaherpesviru
dissemin
vaccin
platform
similar
mv
cmv
immunogen
spread
effici
host
speci
howev
cmv
infect
normal
benign
healthi
host
import
differ
remov
need
use
attenu
strain
therebi
potenti
enabl
use
wildtyp
cmv
preserv
animaltoanim
transmiss
characterist
similar
mv
cmv
also
highli
speciesrestrict
mammalian
host
speci
studi
carri
cmv
speci
barrier
cmv
appear
remark
robust
direct
experiment
inocul
unabl
establish
offspeci
infect
even
close
relat
rhesu
cynomolg
macaqu
cmv
ident
nucleotid
level
recent
studi
show
strict
speci
restrict
extend
cmv
wild
absenc
crossspeci
cmv
transmiss
even
chimpanze
monkey
prey
speci
involv
intim
nhp
relationship
tai
forest
nation
park
cote
ivor
cmv
also
ubiquit
within
host
speci
allow
vaccin
engin
cmv
strain
alreadi
endem
within
target
speci
help
remov
concern
associ
introduct
new
virus
anim
popul
long
establish
biolog
relationship
although
target
eid
decad
work
toward
use
murin
cmv
mcmv
viral
vector
immunocontracept
vaccin
control
mous
plagu
australia
give
insight
applic
dissemin
vaccin
target
high
risk
pathogen
eid
control
mice
directli
infect
mcmv
strain
express
femal
mous
fertil
antigen
develop
prolong
essenti
lifelong
infertil
immunocontracept
depend
antibodi
product
led
ablat
ovarian
follicl
despit
success
mcmv
inject
vaccin
lack
direct
transmiss
uninfect
mice
laboratori
condit
hurdl
develop
transgen
express
mcmv
frequent
associ
salivari
gland
attenu
major
organ
involv
animaltoanim
transmiss
cmv
howev
even
low
passag
nongenet
manipul
wildtyp
strain
mcmv
transmit
poorli
laboratori
condit
therefor
clear
poor
transmiss
vaccin
strain
due
genet
manipul
viru
andor
reflect
gener
lack
viral
transmiss
laboratori
condit
possibl
inabl
transmit
laboratori
condit
may
due
transmiss
characterist
uniqu
rodent
cmv
similar
situat
mcmv
mice
transmiss
sin
nombr
hantaviru
snv
deer
mice
could
demonstr
standard
laboratori
condit
howev
effici
transmiss
observ
follow
cohous
outdoor
enclosur
correl
number
aggress
encount
enumer
number
bite
wound
first
studi
use
cmv
dissemin
vaccin
target
human
eid
use
cmv
deer
mice
peromyscu
cmv
pcmv
target
snv
wild
deer
mous
snv
transmiss
speci
use
pcmv
express
snv
envelop
glycoprotein
pcmv
vaccin
induc
antibodi
follow
direct
inocul
deer
mice
pcmv
induc
immun
durabl
persist
period
associ
lower
level
pcmvspecif
antibodi
compar
wildtyp
pcmv
observ
delay
replic
vitro
combin
lower
antipcmv
antibodi
level
suggest
level
attenu
howev
pcmv
still
abl
induc
immun
healthi
deer
mice
previous
infect
either
pcmv
wildtyp
pcmv
abil
cmv
reinfect
cmv
seroposit
host
characterist
share
cmv
critic
use
viru
dissemin
vaccin
platform
due
cmv
ubiquit
within
mammalian
host
abil
pcmv
transmit
immun
cohous
mice
protect
snv
challeng
determin
howev
studi
suggest
import
use
nonattenu
virusbas
vaccin
platform
wildtyp
characterist
possibl
cmv
given
benign
natur
healthi
host
dissemin
cmvbase
approach
also
develop
toward
control
ebola
viru
wildlif
reservoir
transmiss
speci
africa
approxim
past
human
ebola
viru
outbreak
known
result
direct
handl
infect
ape
carcass
identifi
ape
critic
wildlif
ebola
viru
transmiss
speci
ebola
viru
also
regard
major
threat
surviv
african
ape
popul
wild
consequ
dissemin
cmvbase
strategi
develop
part
ongo
multidisciplinari
effort
human
health
scientist
conservationist
world
wildlif
fund
target
ebola
viru
infect
african
great
ape
bonobo
chimpanze
gorilla
potenti
also
fruit
bat
fruit
bat
rousettu
aegyptiacu
also
known
reservoir
marburg
viru
dissemin
vaccin
platform
target
bat
roost
may
also
therefor
suitabl
interrupt
transmiss
relat
filoviru
recent
seri
studi
shown
cmvbase
vaccin
abl
provid
protect
ebola
viru
challeng
follow
direct
inocul
studi
mcmv
vector
express
cell
epitop
nucleoprotein
np
ebola
viru
fuse
nonessenti
mcmv
protein
mcmvzebovnpctl
shown
induc
durabl
npspecif
immun
month
mcmvzebovnpctl
vaccin
mice
show
evid
ebola
viru
diseas
evd
follow
lethal
ebola
viru
challeng
impress
mice
complet
control
ebola
viru
infect
detect
viremia
remain
mice
show
log
reduct
viremia
rel
nonvaccin
control
protect
longliv
mice
vaccin
singl
dose
mcmvzebovnpctl
protect
evd
follow
lethal
challeng
week
postvaccin
attract
qualiti
dissemin
vaccin
use
wildlif
popul
studi
nhp
ebola
viru
challeng
model
recent
complet
manuscript
review
model
key
question
transmiss
immun
cmv
seroposit
anim
assess
laboratori
mous
model
see
address
experiment
system
translat
nhp
wild
substanti
evid
support
abil
primat
cmv
includ
human
cmv
hcmv
superinfect
seroposit
host
studi
examin
hcmv
seroposit
women
show
frequent
presenc
multipl
glycoprotein
n
gn
andor
gb
variant
within
hcmv
posit
urin
blood
sampl
suggest
individu
infect
multipl
hcmv
strain
subsequ
studi
monitor
develop
hcmv
strainspecif
antibodi
respons
cohort
healthi
seroposit
women
report
particip
develop
new
strainspecif
antibodi
mean
time
month
month
indic
superinfect
rel
common
event
superinfect
cmv
seroposit
nhp
demonstr
experiment
simian
immunodefici
viru
siv
rhesu
macaqu
aid
model
follow
direct
inocul
recombin
rhesu
cmv
rhcmv
genet
modifi
express
siv
antigen
follow
superinfect
recombin
rhcmv
abl
establish
persist
longterm
infect
induc
tcell
respons
express
siv
antigen
compar
observ
rhcmv
seroneg
anim
abil
induc
robust
tcell
respons
new
heterolog
antigen
encod
rhcmv
vector
presenc
prior
cmv
immun
notabl
suggest
origin
antigen
sin
phenomenon
first
observ
influenza
aspecif
antibodi
virusspecif
tcell
respons
lymphocyt
choriomening
viru
mous
model
wherebi
presenc
preexist
immun
blunt
immun
respons
new
crossreact
antigen
may
appli
situat
howev
effect
close
antigen
relat
heterolog
target
antigen
within
context
cmv
infect
need
determin
studi
perform
siv
rhesu
macaqu
model
show
abil
superinfect
depend
gene
region
genom
region
contain
sever
gene
involv
downmodul
mhc
class
antigen
present
tcell
deplet
restor
abil
rhcmv
delet
superinfect
seroposit
anim
indic
superinfect
due
viral
subvers
host
tcell
immun
respons
interestingli
follow
recoveri
tcell
respons
anim
delet
virus
abl
persist
indic
establish
host
tcell
respons
unabl
clear
viru
infect
outsid
mcmv
mous
model
see
abil
recombin
cmv
spread
anim
test
howev
recent
studi
investig
transmiss
rhcmv
cohous
anim
show
nonrecombin
tissu
culturepassag
rhcmv
strain
maintain
abil
shed
bodili
fluid
saliva
urin
level
compar
wildtyp
rhcmv
provid
region
genom
encod
sever
gene
involv
tropism
immun
evas
call
ulb
region
intact
cmv
transmiss
gener
believ
involv
mucos
exposur
fluid
well
genit
secret
breast
milk
consist
maintain
shed
characterist
tissu
culturepassag
virus
also
retain
abil
spread
cohous
rhcmvseroposit
anim
observ
indic
least
possibl
laboratori
manipul
cmv
strain
maintain
abil
wildtyp
transmiss
studi
need
ensur
recombin
cmv
express
heterolog
target
antigen
similarli
maintain
wildtyp
transmiss
targetspecif
immun
respons
follow
transmiss
experi
studi
explor
use
dissemin
vaccin
target
pathogen
see
expect
prove
invalu
studi
especi
regard
import
avoid
vaccin
attenu
maintain
wildtyp
characterist
cmv
transmiss
studi
frequenc
cmv
infect
natur
transmiss
anim
popul
approach
consist
epidemiolog
studi
human
major
peak
infect
occur
earli
host
age
essenti
us
primat
center
rhesu
macaqu
rhcmv
seroposit
age
one
year
environment
stress
siv
infect
chimpanze
result
immun
suppress
anim
wild
therefor
also
import
ensur
cmvbase
vaccin
present
higher
risk
immunecompromis
anim
wildtyp
cmv
strain
alreadi
infect
becom
clear
emerg
pathogen
repres
greatest
risk
global
health
like
transmit
key
anim
speci
poorer
area
world
recent
histori
also
tell
us
pathogen
probabl
never
seen
ebola
viru
outbreak
show
differ
healthcar
infrastructur
humantohuman
transmiss
eid
time
overal
healthcar
infrastructur
countri
rais
level
enabl
identif
control
highrisk
eid
sourc
global
commun
fate
reactiv
respons
eid
outbreak
innov
strategi
therefor
urgent
requir
identifi
preemptiv
control
eid
underresourc
hotspot
region
selfdissemin
vaccin
one
innov
approach
may
potenti
overcom
problem
associ
use
convent
vaccin
preemptiv
pathogen
control
highvalu
anim
popul
within
challeng
environ
although
still
rel
earli
stage
nascent
field
selfdissemin
transmiss
vaccin
potenti
solv
mani
current
intract
public
health
conserv
problem
address
convent
vaccin
tabl
identif
geograph
hotspot
highvalu
wildlif
speci
eid
begin
enabl
inform
decis
alloc
finit
resourc
protect
global
health
recognit
chang
think
usaid
ept
program
collabor
multipl
partner
aim
monitor
increas
local
capac
geograph
hot
spot
identifi
emerg
new
infecti
diseas
highrisk
wildlif
bat
rodent
nonhuman
primat
identif
anim
pathogen
destin
becom
signific
eid
within
human
popul
still
remain
beyond
current
technic
capac
howev
initi
poor
adapt
mani
emerg
zoonot
pathogen
may
provid
window
opportun
initi
stutter
transmiss
phase
human
enabl
nascent
eid
target
within
anim
host
stage
still
amen
control
follow
pathogen
identif
selfdissemin
vaccin
platform
provid
one
mean
preemptiv
control
emerg
pathogen
adapt
new
technolog
also
greatli
increas
eas
speed
new
vaccin
vector
construct
follow
identif
target
pathogen
next
five
year
potenti
place
us
posit
abl
achiev
high
vaccin
coverag
nascent
zoonot
pathogen
anim
speci
involv
transmiss
otherwis
inaccess
convent
vaccin
mani
highrisk
zoonot
pathogen
reduct
zoonot
flow
human
popul
may
decreas
probabl
complet
adapt
human
host
global
signific
jarvi
aa
murphi
declar
conflict
interest
patent
applic
jarvi
uk
applic
jarvi
aa
murphi
author
would
like
acknowledg
support
school
biomed
healthcar
scienc
plymouth
univers
jarvi
aa
murphi
mari
programm
jarvi
institut
immunolog
infecti
diseas
murdoch
univers
aj
redwood
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
key
issu
emerg
infecti
diseas
eid
place
increas
burden
human
health
infrastructur
increas
rate
eid
incid
directli
link
human
activitycurr
fund
paradigm
often
focu
wealthi
countri
rather
develop
countri
contain
geograph
eid
hotspot
fund
paradigm
leav
world
illprepar
detect
control
diseasestarget
zoonot
pathogen
wildlif
popul
vaccin
potenti
power
method
reduc
transmiss
eid
direct
vaccin
anim
may
hamper
number
obstacl
includ
poor
infrastructur
support
necessari
cold
chain
inaccess
anim
speci
inhospit
terrain
costvaccin
capabl
selfdissemin
may
overcom
mani
hurdl
face
direct
administr
convent
vaccin
selfdissemin
vaccin
need
display
speci
specif
immunogen
normal
transmiss
dynam
cytomegaloviru
cmv
base
viral
vector
potenti
fulfil
mani
requir
includ
nativ
endem
target
anim
speci
proof
concept
studi
use
direct
inocul
cmvbase
vaccin
vector
perform
viral
pathogen
sin
nombr
hantaviru
ebola
viru
cmvbase
vaccin
vector
also
use
success
proof
concept
viral
vector
immunocontraceptionproduct
cmvbase
vaccin
proven
capac
transmit
next
step
develop
selfdissemin
vaccin
